Illumina Inc. (NASDAQ ... delivering the NovaSeq X single-flow-cell system alongside a cutting-edge software upgrade and new kits.

It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation ...

The US Single-Cell Analysis Market is projected to reach US$2,695.3 million by 2029 from an estimated US$1,378.6 million in 2024, at a CAGR ...

It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation ...

Gut microbiota composition and sex hormones influence the immune response to methicillin-resistant Staphylococcus aureus gastrointestinal colonization in mice.

Grail’s cutting-edge cancer blood test has stirred investor excitement many times in the past few years. With the stock down 55% from its February peak, Canaccord Genuity issued a Buy recommendation ...

Illumina ranks as the largest player in genetic ... test panels, reagents, and flow cells. Services often contribute 10% or more to revenue and help increase customer value by improving sequencing ...